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Using a Bayesian approach to clinical trial design is becoming more common. For example, at the MD
Anderson Cancer Center, Bayesian techniques are routinely employed in the design and analysis of Phase
I and II trials. It is important that the operating characteristics of these procedures be determined as part of
the process when establishing a stopping rule for a clinical trial. This study determines the power function
for some common fixed-sample procedures in hypothesis testing, namely the one and two-sample tests
involving the binomial and normal distributions. Also considered is a Bayesian test for multi-response
(response and toxicity) in a Phase II trial, where the power function is determined.
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Introduction
primary consideration in designing Phase I and
II studies. Of related interest in the design of a
trial is the estimation of sample size based on
Bayesian principles, where Smeeton and Adcock
(1997) provided a review of formal decisiontheoretic ideas in choosing the sample size.
Typically, the statistician along with the
investigator will use information from previous
related studies to formulate the null and
alternative hypotheses and to determine what
prior information is to be used for the Bayesian
analysis. With this information, the Bayesian
design parameters that determine the critical
region of the test are given, the power function
calculated, and lastly the sample size determined
as part of the design process. In this study, only
fixed-sample size procedures are used.
First, one-sample binomial and normal
tests will be considered, then two-sample tests
for binomial and normal populations, and lastly
a test for multinomial parameters of a multiresponse Phase II will be considered. For each
test, the null and alternative hypotheses will be
formulated and the power function determined.
Each case will be illustrated with an example,
where the power function is calculated for
several values of the Bayesian design
parameters.

The Bayesian approach to testing hypotheses is
becoming more common. For example, in a
recent review volume, see Crowley (2001),
many
contributions
where
Bayesian
considerations play a prominent role in the
design and analysis of clinical trials. Also, in an
earlier Bayesian review (Berry & Stangl, 1996),
methods are explained and demonstrated for a
wide variety of studies in the health sciences,
including the design and analysis of Phase I and
II studies.
At our institution, the Bayesian
approach is often used to design such studies.
See Berry (1985,1987,1988), Berry and Fristed
(1985), Berry and Stangl (1996), Thall and
Russell (1998), Thall, Estey, and Sung (1999),
Thall, Lee, and Tseng (1999), Thall and Chang
(1999),and Thall et al. (1998), for some recent
references where Bayesian ideas have been the
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ON THE POWER FUNCTION OF BAYESIAN TESTS
critical region of the test, thus the power
function of the test is

Methodology
For the design of a typical Phase II trial, the
investigator and statistician use prior
information on previous related studies to
develop a test of hypotheses. If the main
endpoint is response to therapy, the test can be
formulated as a sample from a binomial
population, thus if Bayesian methods are to be
employed, prior information for a Beta prior
must be determined. However, if the response is
continuous, the design can be based on a onesample normal population. Information from
previous related studies and from the
investigator’s experience will be used to
determine the null and alternative hypotheses, as
well as the other design parameters that
determine the critical region of the test.
The critical region of a Bayesian test is
given by the event that the posterior probability
of the alternative hypothesis will exceed some
threshold value. Once a threshold value is used,
the power function of the test can be calculated.
The power function of the test is determined by
the sample size, the null and alternative
hypotheses, and the above-mentioned threshold
value.
Results
Binomial population
Consider a random sample from a
Bernoulli population with parameters n and θ ,
where n is the number of patients and θ is the
probability of a response. Let X be the number
of responses among n patients, and suppose the
null hypotheses is H: θ ≤ θ 0 versus the
alternative A: θ > θ 0 . From previous related
studies and the experience of the investigators,
the prior information for θ is determined to be
Beta(a,b), thus the posterioir distribution of θ is
Beta (x+a, n-x+b), where x is the observed
number of responses among n patients. The null
hypothesis is rejected in favor of the alternative
when
Pr[ θ >θ 0 / x, n] > γ ,

(1)

where γ is usually some large value as .90, .95,
or .99. The above equation determines the

g( θ ) = Pr X / θ {Pr[θ > θ 0 / x, n] > γ },

(2)

where the outer probability is with respect to the
conditional distribution of X given θ . The
power (2) at a given value of θ is interpreted as
a simulation as follows:
(a) select (n, θ ), and set S=0,
(b) generate a X~Binomial(n, θ ),
(c) generate a θ ~Beta(x+a, n-x+b),
(d) if Pr [ θ > θ 0 / x, n] > γ , let the counter S
=S+1, otherwise let S=S,
(e) repeat (b)-(d) M times, where M is ‘large’,
and
(f) select another θ and repeat (b)-(d).
The power of the test is thus S/M and
can be used to determine a sample size by
adjusting the threshold γ , the probability of a

Type I error g( θ 0 ), and the desired power at a
particular value of the alternative. The approach
taken is fixing the Type I error at α and finding
n so that the power is some predetermined value
at some value of θ deemed to be important by
the design team. This will involve adjusting the
critical region by varying the value of the
threshold γ . An example of this method is
provided in the next section. The above
hypotheses are one-sided, however it is easy to
adjust the above testing procedure for a sharp
null hypothesis.
Normal Population
Let N( θ ,τ ) denote a normal
population with mean θ and precision τ ,
where both are unknown and suppose we want
to test the null hypothesis H: θ = θ 0 versus A:
−1

θ ≠ θ 0 , based on a random sample X of size n
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_

x

with sample mean

and variance

s

2

. Using a

non-informative prior distribution for θ and τ ,
the Bayesian test is to reject the null in favor of
the alternative if the posterior probability P of
the alternative hypothesis satisfies
P > γ , where

(3)

P = D 2 /D

(4)

and, D = D 1 + D 2 .
It can be shown that
D 1 = {πΓ (n/2)}2
[ n(θ 0 -

n/2

} /{(2 π )

n/2
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it can be shown that the power (size) of the test
at θ 0 is 1- γ . Thus in this sense, the Bayesian
and classical t-test are equivalent.
Two binomial populations
Comparing two binomial populations is
a common problem in statistics and involves the
null hypothesis H: θ 1 = θ 2 versus the

alternative A: θ 1 ≠ θ 2 , where θ 1 and θ 2 are
parameters from two Bernoulli populations.
Assuming uniform priors for these two
populations, it can be shown that the Bayesian
test is to reject H in favor of A if the posterior
probability P of the alternative hypothesis
satisfies

_

x ) 2 + (n-1) s 2 ] n / 2 }

(5)

P > γ , where

(8)

P = D 2 /D,

(9)

and

D 2 = {(1- π ) Γ ((n-1)/2) 2
/{n

1/ 2

(2 π )

( n −1) / 2

[(n-1)

s

2

( n −1) / 2

]

}

( n −1) / 2

}

(6)

where π is the prior probability of the null
hypothesis.
The power function of the test is
g( θ ,τ ) =

Pr X / θ ,τ [ P >

θ ∈ R and τ >0

γ

_

/ n,

x, s 2 ],
(7)

where P is given by (3) and the outer probability
is with respect to the conditional distribution of
X given θ and τ .
The above test is for a two-sided
alternative, but the testing procedure is easily
revised for one-sided hypotheses. This will be
used to find the sample size in an example to be
considered in a following section.
In the case when the null and alternative
hypotheses are H: θ ≤ θ 0 and A: θ > θ 0 and
the prior distribution for the parameters is
f( θ ,τ ) ∝ 1 / τ , where H is rejected in favor of
A whenever
Pr[θ

_

> θ 0 /n, x, s 2 ] > γ

,

and D = D 1 + D 2 . It can be shown that

π BC(n :x

: x2 )
Γ( x1 + x2 + 1)Γ(n1 + n2 − x1 − x2 ) }
÷ Γ(n1 + n2 + 2) ,

D1 = {

1

1

)BC( n2

where BC(n,x) is the binomial coefficient “x
from n”. Also, D 2 = (1- π )(n 1 +1) (n 2 +1) ,
where π is the prior probability of the null
−1

−1

hypothesis. X 1 and X 2 are the number of
responses from the two binomial populations
with parameters (n 1 , θ 1 ) and ( n2 ,θ 2 )
respectively. The alternative hypothesis is twosided, however the testing procedure is easily
revised for one-sided hypotheses.
In order to choose sample sizes n 1 and
n 2 , one must calculate the power function
g( θ 1 ,θ 2 )

=

Pr x , x
1

2

/ θ1 ,θ 2

[P

>

γ

/

x1 , x2 , n1 , n2 ], (θ1 ,θ 2 )∈ (0,1) x (0,1)
(10)
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where P is given by
(9) and the outer
probability is with respect to the conditional
distribution of X 1 and X 2 , given θ 1 and θ 2 .
As given above, (10) can be evaluated by a
simulation procedure similar to that described in
3.1.
Two normal populations
Consider two normal populations with
means θ 1 and θ 2 and precisions τ 1 and τ 2
respectively, and suppose the null and
alternative hypotheses are H: θ 1 ≤ θ 2 and A:

θ 1 >θ 2

respectively.
Assuming a noninformative prior for the parameters, namely
f( θ 1 ,θ 2 ,τ 1,τ 2 ) = 1/τ 1τ 2 , one can show that
the posterior distribution of the two means is
such that θ 1 and θ 2 are independent and θ i
_

/data ~ t(n i -1,

xi

2

n i / si ), where n i is the

_

sample size and

xi and si

2

are the sample mean

and variance respectively.
That is, the posterior distribution of

θi

is a t distribution with n i -1 degrees of freedom,
_

mean

x i , and precision n i / si

(θ i -

_

x i )(

2 1/ 2

n i / si )

2

. It is known that

has a Student’s t-

distribution with n i -1 degrees of freedom.
Therefore the null hypothesis is rejected
if

Pr[θ 1 >θ 2 /data]> γ .

(11)

The multinomial model is quite relevant
to the Phase II trial where the k categories
represent various responses to therapy. Let
θ = (θ1 ,θ 2 ,...,θ k ) , then if a uniform prior
distribution is appropriate, the posterior
distribution is
f( θ / data)

i =k

∝ ∏θ i n

∑θ =
i =k

i

,

i =1

0 < θ i < 1 for i=1,2,…,k.
and
( n1

the

distribution

i =1

i

(12)
is

∑θ
i =k

i= 1,2,…,k, where

i =1

i

= 1 and

0 < θi < 1

for i=1,2,…,k. Suppose there are n patients and
that n i belong to the i-th category.

Dirichlet

+ 1, n2 + 1,..., nk + 1) .

A typical hypothesis testing problem,
see [14], is given by the null hypothesis ( k=4),
where
H: θ 1 + θ 2 ≤ k12 orθ 1 + θ 3 ≥ k13
versus the alternative
A: θ 1

+ θ 2 > k12 andθ1 + θ 3 < k13 .

The null hypothesis states that the response rate
θ1 + θ 2 is less than some historical value or
that the toxicity rate

θ1 + θ 3

some historical value

k13 . The null hypothesis

is greater than

is rejected if the response rate is larger than the
historical or the toxicity rate is too low
compared to the historical.
Pr[ A /data]> γ

(13)

where γ is some threshold value. This
determines the critical region of the test, thus the
power function is
g( θ )= Pr n / θ { Pr[ A / data] >

Multinomial Populations
Consider a multinomial population with
k categories and corresponding probabilities θ i ,

1, and

γ },

(14)

where the outer probability is with respect to the
conditional distribution of

n = (n1 , n2 ,..., nk )

given

θ.

The power function will be illustrated
for the multinomial test of hypothesis with a
Phase I trial, where response to therapy and
toxicity are considered in designing the trial.

BROEMELING & WU
Examples
The above problems in hypothesis
testing are illustrated by computing the power
function of some Bayesian tests that might be
used in the design of a Phase II trial.
One-Sample Binomial
No prior information
Consider a typical Phase II trial, where
the historical rate for toxicity was determined as
.20. The trial is to be stopped if this rate exceeds
the historical value. See Berry (1993) for a good
account of Bayesian stopping rules in clinical
trials. Toxicity rates are carefully defined in the
study protocol and are based on the NCI list of
toxicities. The null and alternative hypotheses
are given as
H: θ

≤ .20

and A: θ

> .20 ,

(15)

where θ is the probability of toxicity. The null
hypothesis is rejected if the posterior probability
of the alternative hypothesis is greater than the
threshold value γ .
The power curve for the following
scenarios will be computed (see Equation 2),
with sample sizes n = 125, 205, and 500,
threshold values γ = .90, .95, .99, M=1000, and

null value θ 0 = .20.
It is seen that the power of the test at
θ = .30 and γ = .95, is .841, .958, and .999 for
n = 125, 205, and 500, respectively.
Note that for a given N and γ , the

power increases with θ and for given N and θ ,
the power decreases with γ , and for given γ
and

θ,

the power of course increases with N.
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The Bayesian test behaves in a
reasonable way. For the conventional type I
error of .05, a sample size of N=125 would be
sufficient to detect the difference .3 versus .2
with a power of .841. It is interesting to note that
the usual binomial test, with alpha = .05 and
power .841, requires a sample of size 129 for the
same alternative value of θ . For the same alpha
and power, one would expect the Bayesian (with
a uniform prior for θ ) and the binomial tests to
behave in the same way in regard to sample size.
With prior information
Suppose the same problem is considered
as above, but prior information is available with
50 patients, 10 of whom have experienced
toxicity. The null and alternative hypotheses are
as above, however the null is rejected whenever
(16)
Pr[θ > φ / x, n] > γ ,
where θ is independent of φ ~ Beta(10,40).
This can be considered as a one-sample problem
where a future study is to be compared to a
historical control.
As above, compute the power function
(see Table 2) of this Bayesian test with the same
sample sizes and threshold values in Table 1.
The power of the test is .758, .865, and .982 for
θ = .4 for N= 125, 205, and 500, respectively.
This illustrates how important is prior
information in testing hypotheses. If the
hypothesis is rejected with the critical region
Pr[ θ >.2 / x, n] > γ ,
(17)
the power (Table 1) will be larger than the
corresponding power (Table 2) determined by
the critical region (16), because of the additional
posterior variability introduced by the historical
information contained in φ . Thus, larger sample
sizes are required with (16) to achieve the same
power as with the test given by (17).
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Table 1. Power function for H versus A, N=125,205,500.

θ
0
.1
.2
.3
.4
.5
.6
.7
.8
.9
1.0

γ

.90
0,0,0
0,0,0
.107,.099,.08
.897,.97,1
1,1,1
1,1,1
1,1,1
1,1,1
1,1,1
1,1,1
1,1,1

.95
0,0,0
0,0,0
.047,.051,.05
.841,.958,.999
1,1,1
1,1,1
1,1,1
1,1,1
1,1,1
1,1,1
1,1,1

.99
0,0,0
0,0,0
.013,.013,.008
.615,.82,.996
.996,1,1
1,1,1
1,1,1
1,1,1
1,1,1
1,1,1
1,1,1

Table 2. Power function for H versus A, N=125,205,500.

θ
0
.1
.2
.3
.4
.5
.6
.7
.8
.9
1.0

γ

.90
0,0,0
0,0,0
.016,.001,.000
.629,.712,.850
.996,.999,1
1,1,1
1,1,1
1,1,1
1,1,1
1,1,1
1,1,1

Two Binomial Populations
The case of two binomial populations
was introduced in section 4.2, where equation
(10) gives the power function for testing H:
θ1 = θ 2 versus the alternative A: θ1 ≠ θ 2 .
In this example, let n 1 = 20 = n 2 be the
sample sizes of the two groups and suppose the
prior probability of the null hypotheses is π =
.5. The power at each point ( θ 1 ,θ 2 ) is
calculated via simulation, using equation (10)
with γ = .90. Table 3 lists the power function
for this test.

.95
0,0,0
0,0,0
.002,.000,.000
.362,.374,.437
.973,.998,1
1,1,1
1,1,1
1,1,1
1,1,1
1,1,1
1,1,1

.99
0,0,0
0,0,0
.000,.000,.000
.004,.026,.011
.758,.865,.982
.999,1,1
1,1,1
1,1,1
1,1,1
1,1,1
1,1,1

When the power is calculated with the
usual two-sample, two-tailed, binomial test with
alpha = .013, sample sizes n 1 = 20 = n 2 , and

(θ 1 ,θ 2 ) = (.3, .9), the power is .922, which is
almost equivalent to the above Bayesian test.
This is to be expected, because we are using a
uniform prior density for both Bernoulli
parameters. It is not too uncommon to have two
binomial populations in a Phase II setting, where
θ1 and θ 2 are response rates to therapy.

BROEMELING & WU
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Table 3. Power for Bayesian Binomial Test.

θ2
θ1

.1

.2

.3

.4

.5

.6

.7

.8

.9

1

.1

.004

.032

.135

.360

.621

.842

.958

.992

1

1

.2

.031

.011

.028

.106

.281

.536

.744

.913

.997

1

.3

.171

.028

.006

.029

.107

.252

.487

.767

.961

1

.4

.368

.098

.025

.013

.028

.075

.244

.542

.847

.999

.5

.619

.289

.100

.022

.007

.017

.108

.291

.640

.981

.6

.827

.527

.237

.086

.035

.005

.027

.116

.357

.882

.7

.950

.775

.464

.254

.113

.037

.013

.049

.171

.587

.8

.996

.928

.768

.491

.316

.132

.028

.010

.040

.205

.9

1

.996

.946

.840

.647

.359

.156

.037

.006

.014

1

1

1

1

1

.984

.873

.567

.200

.017

.000

A Phase II trial with toxicity and response rates
With Phase II trials, response to therapy
is usually taken to be the main endpoint,
however in reality one is also interested in the
toxicity rate, thus it is reasonable to consider
both when designing the study. Most Phase II
trials are conducted not only to estimate the
response rate, but to learn more about the
toxicity. In such a situation, the patients can be
classified by both endpoints as follows:
Table 4. Number of and Probability of Patients
by Response and Toxicity.
Toxicity
Response
Yes
No
Yes
(n , θ )
(n , θ )
1

No

1

(n 3 , θ 3 )

2

2

(n 4 , θ 4 )

θ r = θ1 + θ 2
and the rate of toxicity be θ t = θ 1 + θ 3 , where
θ1 is the probability a patient will experience
Let the response rate be

toxicity and respond to therapy, and n 1 is the
number of patients who fall into that category.
Following Petroni and Conoway (2001), let the
null hypothesis be
H: θ r

≤ θr0

or θ t

≥ θt0

and the alternative hypothesis be
A: θ r

> θr0

and θ t

< θt0 ,

where θ r 0 and θ t 0 are given and estimated by
the historical rates in previous trials.
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Table 5. Power of Bayesian Multinomial Test.

θt

.2

.3

.4

.5

.000
.000
.070
.600
.794
.818
.822

.000
.000
.002
.114
.154
.158
.084

.000
.000
.000
.000
.000
.000
.000

.000
.000
.000
.000
.000
.000
.000

θr
.2
.3
.4
.5
.6
.7
.8

In this example, let

θt0 =

θr0

= .40 and

.30. That is, the alternative hypothesis is
that the response rate exceeds .40 and the
toxicity rate is less than .30, and the null is
rejected in favor of the alternative if the latter
has a posterior probability in excess of γ .
Table 5 gives the power for n=100 patients and
threshold γ = .90.
From above, the power of the test is
.818 when ( θ r ,θ t ) = (.7, .2), and the test
behaves in a reasonable way.
When the
parameter values are such that the response rate
is in excess of .40 and the toxicity rate is less
than or equal to .30, the power is higher, relative
to those parameter values when the null
hypothesis is true.
Conclusion
We have provided a way to assess the sampling
properties of some Bayesian tests of hypotheses
used in the design and analysis of Phase II
clinical trials.
The one-sample binomial scenario is the
most common in a Phase II trial, where the
response to therapy is typically binary. We think
it is important to know the power function of a
critical region that is determined by Bayesian
considerations, just as it is with any other test.

The Bayesian approach has one major
advantage and that is prior information, and
when this is used in the design of the trial, the
power of the test will be larger then if prior
information had not been used.
We have confined this investigation to
the fixed-sample case, but will seek to expand
the results to the more realistic situation where
Bayesian sequential stopping rules will be used
to design Phase II studies.
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